Yep. They’d rather take Gilead money. I get it, no worries. I have a feeling they’ll be embarrassed rather soon if Leronlimab and Remdesivir aren’t in a combo standard of care.
Hard to argue with Gilead poor data. Leronlimab has the data in their favor.